Odyssey Therapeutics

The company's business is centered on creating a sustainable pipeline of therapeutics for cancer and inflammatory diseases affecting large patient populations. Odyssey has established a highly integrated drug discovery engine that combines advanced computational tools, including artificial intelligence and machine learning, with deep expertise in chemistry and biology to tackle challenging drug targets. This engine is designed to accelerate the identification and development of both small-molecule and protein-based therapies. The company's revenue model is predicated on the successful development and commercialization of its product candidates, which involves substantial investment in research and development funded by significant venture capital.

Odyssey's discovery platform is a key differentiator, integrating physics-based molecular simulations, AI, and machine learning to unlock high-value targets, some of which were previously considered undruggable. In a strategic move to bolster these capabilities, the company acquired Rahko, a quantum machine learning company, in January 2022. This acquisition integrated a platform that uses computational chemistry, machine learning, and quantum computing to better simulate drug behavior and identify novel binding sites. Odyssey's pipeline includes multiple preclinical programs in immunology and oncology. The company has raised substantial capital to advance these programs toward clinical trials, securing a $218 million Series A in December 2021, a $168 million Series B in October 2022, and a $101 million Series C in December 2023, bringing its total funding to nearly $500 million within its first few years.